- Insulin icodec, a once-weekly basal insulin analogue, has glucose-lowering and safety profiles similar to once-daily glargine.
Why this matters
- A once-weekly formulation could improve patient adherence.
- Randomized, double-blind, double-dummy, 26-week phase 2 trial of once-weekly icodec vs daily glargine U100 in 247 insulin-naive patients with type 2 diabetes who had HbA1c 7.0%-9.5% while taking metformin +/− a dipeptidyl peptidase 4 inhibitor.
- Funding: Novo Nordisk.
- Mean HbA1c dropped from:
- 8.09% to 6.69% with icodec and
- 7.96% to 6.87% with glargine.
- −1.33 vs −1.15 percentage points (P=.08).
- Estimated percentages of patients reaching HbA1c
- 72% with icodec vs 68% with glargine.
- Estimated OR: 1.20 (95% CI, 0.98-2.13).
- 0.53 with icodec.
- 0.46 with glargine.
- Estimated rate ratio: 1.09 (95% CI, 0.45-2.65).
- Not powered to detect significant differences between treatments for any endpoint.
- Insulin adjustments not tailored for each treatment.
- Patients using sulfonylureas were excluded.